Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer

Immune checkpoint inhibitors (ICPis) have revolutionized cancer therapy with broad activities against a wide range of malignancies. However, in many malignancies their efficacy remains limited due to the primary resistance. Furthermore, a high percentage of patients develop progression due to the se...

Descripción completa

Detalles Bibliográficos
Autores principales: Seto, Tiffany, Sam, Danny, Pan, Minggui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410194/
https://www.ncbi.nlm.nih.gov/pubmed/30678257
http://dx.doi.org/10.3390/medsci7020014
_version_ 1783402185565929472
author Seto, Tiffany
Sam, Danny
Pan, Minggui
author_facet Seto, Tiffany
Sam, Danny
Pan, Minggui
author_sort Seto, Tiffany
collection PubMed
description Immune checkpoint inhibitors (ICPis) have revolutionized cancer therapy with broad activities against a wide range of malignancies. However, in many malignancies their efficacy remains limited due to the primary resistance. Furthermore, a high percentage of patients develop progression due to the secondary resistance even after obtaining a response or achieving a stable disease. In this review, we will discuss the mechanisms that underlie the primary and secondary resistance to ICPis in cancer immunotherapy and provide an overview to impart a broad understanding of the critical issues that are encountered in clinical oncology practice.
format Online
Article
Text
id pubmed-6410194
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64101942019-03-25 Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer Seto, Tiffany Sam, Danny Pan, Minggui Med Sci (Basel) Review Immune checkpoint inhibitors (ICPis) have revolutionized cancer therapy with broad activities against a wide range of malignancies. However, in many malignancies their efficacy remains limited due to the primary resistance. Furthermore, a high percentage of patients develop progression due to the secondary resistance even after obtaining a response or achieving a stable disease. In this review, we will discuss the mechanisms that underlie the primary and secondary resistance to ICPis in cancer immunotherapy and provide an overview to impart a broad understanding of the critical issues that are encountered in clinical oncology practice. MDPI 2019-01-22 /pmc/articles/PMC6410194/ /pubmed/30678257 http://dx.doi.org/10.3390/medsci7020014 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Seto, Tiffany
Sam, Danny
Pan, Minggui
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
title Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
title_full Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
title_fullStr Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
title_full_unstemmed Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
title_short Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
title_sort mechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410194/
https://www.ncbi.nlm.nih.gov/pubmed/30678257
http://dx.doi.org/10.3390/medsci7020014
work_keys_str_mv AT setotiffany mechanismsofprimaryandsecondaryresistancetoimmunecheckpointinhibitorsincancer
AT samdanny mechanismsofprimaryandsecondaryresistancetoimmunecheckpointinhibitorsincancer
AT panminggui mechanismsofprimaryandsecondaryresistancetoimmunecheckpointinhibitorsincancer

Ejemplares similares